Aardvark Therapeutics (AARD) Income from Continuing Operations (2024 - 2026)
Aardvark Therapeutics (AARD) posted Income from Continuing Operations of 21575000.0 for Q1 2026, down 22.73% sequentially from 17579000.0 in Q4 2025, and down 132.09% YoY from 67234730.14 in Q1 2025.
Aardvark Therapeutics (AARD) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Income from Continuing Operations for 3 years, with the latest figure at 21575000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 132.09% year-over-year to 21575000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 69882000.0 (down 127.08% YoY) and the FY2025 annual result came in at 69946000.0, down 80.24% from the prior year.
- Income from Continuing Operations fell to 21575000.0 in Q1 2026 per AARD's latest filing, from 17579000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 2068000.0 in Q1 2024 and troughed at 21575000.0 in Q1 2026.
- A 3-year average of 11413777.78 and a median of 11908000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 47.62% in 2025, down 349.52% in 2025.
- Over 3 years, Income from Continuing Operations stood at 11908000.0 in 2024, then slumped by 47.62% to 17579000.0 in 2025, then declined by 22.73% to 21575000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 21575000.0, 17579000.0, and 16352000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Aardvark Therapeutics | 147.46 Mn | 73.54 Mn | - | -14.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.39 Mn |
| Mar 31, 2026 | -21.58 Mn |
| Dec 31, 2025 | -17.58 Mn |
| Sep 30, 2025 | -16.35 Mn |
| Jun 30, 2025 | -14.38 Mn |
| Mar 31, 2025 | -9.30 Mn |
| Dec 31, 2024 | -11.91 Mn |
| Sep 30, 2024 | -4.09 Mn |
| Jun 30, 2024 | -5.48 Mn |
| Mar 31, 2024 | -2.07 Mn |